FindTrial
Sign In

Fam-Trastuzumab Deruxtecan-Nxki

DRUG4 trials

Sponsors

Strata Oncology, Enliven Therapeutics, QuantumLeap Healthcare Collaborative, Memorial Sloan Kettering Cancer Center

Conditions

Adenocarcinoma of the ColonAdenocarcinoma of the RectumAdvanced Solid TumorCancerColorectal CancerER Positive Breast CancerEstrogen Receptor Positive TumorHER-2 Protein Overexpression

Phase 1

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Active, not recruitingNCT05650879
Enliven TherapeuticsHER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer +1
Start: 2023-03-20End: 2026-07-31Target: 198Updated: 2025-07-15
PRE-I-SPY Phase I/Ib Oncology Platform Program
RecruitingNCT05868226
QuantumLeap Healthcare CollaborativeER Positive Breast Cancer, Estrogen Receptor Positive Tumor, HER2 Low Breast Cancer +18
Start: 2023-02-15End: 2029-12-30Target: 124Updated: 2025-04-04

Phase 2

StrataPATH™ (Precision Indications for Approved Therapies)
TerminatedNCT05097599
Strata OncologyAdvanced Solid Tumor, Cancer
Start: 2022-04-29End: 2024-06-12Updated: 2025-01-08
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Not yet recruitingNCT07691489
Memorial Sloan Kettering Cancer CenterAdenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Colorectal Cancer
Start: 2026-08-01End: 2029-06-01Target: 27Updated: 2026-07-09

Related Papers

Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
Clinical Cancer Research2026-02-17
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).
Journal of Clinical Oncology2024-06-011 citations
Abstract CT059: StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population
Cancer Research2023-04-14